Harvard Bioscience, Inc. provided revenue guidance for the year 2023. The company now expect fiscal 2023 revenue to be approximately flat as compared to 2022. Expected 2023 revenue includes an approximately 5% point headwind from discontinued products.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3.62 USD | +1.69% | -2.16% | -32.34% |
Apr. 09 | Harvard Bioscience Reducing Headcount | MT |
Apr. 09 | Harvard Bioscience, Inc. Announces Action to Improve Operational Efficiency and Support Ongoing Investments in Growth | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-32.34% | 157M | |
+8.07% | 219B | |
+6.59% | 183B | |
+11.26% | 133B | |
+26.57% | 108B | |
+0.65% | 63.06B | |
+13.35% | 52.02B | |
-0.62% | 48.2B | |
-0.93% | 40.37B | |
+11.54% | 39.35B |
- Stock Market
- Equities
- HBIO Stock
- News Harvard Bioscience, Inc.
- Harvard Bioscience, Inc. Provides Revenue Guidance for the Year 2023